Abstract 3820
Background
Head and neck squamous cell carcinoma (HNSCC) is an important malignancy in Taiwan. Anti-PD-1, including nivolumab or pembrolizumab (pembro), had shown the efficacies against recurrent or metastatic (R/M) HNSCC. Afatinib, an irreversible EGFR tyrosine kinase inhibitor (TKI), had showed its activity against head and neck squamous cell carcinoma. In vitro and animal study showed that afatinib can inhibit macrophage function, increase antigen presentation, and augment the T cell response. The role of afatinib for cancer immunotherapy have not been explored in human. We hypothesized that adding afatinib with pembro may improve the treatment efficacy for patients with R/M HNSCC.
Methods
For HNSCC patients who decided to take pembro, the combination with afatinib would be discussed between the physician and the patient. Pembro was planned for 4 cycles. Afatinib was prescribed concurrently with pembro, and will be kept after discontinuation of pembro, until disease progression. For patients taking pembrolizumab and afatinib (P+A), the medical records were reviewed. Patients who have monotherapy with pembrolizumab or afatinib before the P+A were excluded. RECIST 1.1 were used for evaluating tumor response.
Results
From Nov. 1, 2016 to Sep. 30, 2017, 41 R/M HNSCC patients (pts) took P+A. The median age was 59 years, and 38 pts were men. The cancer types were: oral cavity: 29 pts, oropharynx: 5 pts, and hypopharynx: 7 pts. The initial treatments were: pembrolizumab 200mg: 27pts; 2mg/kg: 14pts. Eighteen pts are platinum naïve, and 23 pts are platinum refractory. Until Mar. 30, 2018, the median follow-up was 7.6 months. The clinical response was: CR+PR 24/41 (58.5%, 95% CI: 42.8% -74.3%), SD: 9/41, PD: 8/41. The median PFS was 7.2 (5.0-9.3) months. The median of OS was not reached. The most common toxicities were: diarrhea 56%, skin rash 44%, mucositis 32%, and hand-foot-skin reaction 24%. The incidence of grade 3 or 4 toxicities was 3/41. No pneumonitis were noted in the cohort.
Conclusions
The addition of afatinib with pembrolizumab showed good efficacies and tolerable toxicities. Biomarker studies are ongoing. Further confirmatory prospective trial is indicated.
Clinical trial identification
Legal entity responsible for the study
Hsiang-Fong Kao.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4784 - Tranilast inhibits TGF-beta-induced EMT and invasion/metastasis via the suppression of Smad4 in lung cancer cell lines.
Presenter: Koji Takahashi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
767 - Integrin beta-like 1 overexpression stimulates invasiveness of ovarian cancer cells in vitro
Presenter: Alexander Cortez
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
938 - MiR-449a suppresses endometrial cancer invasion and metastasis by targeting NDRG1
Presenter: Lihua Qiu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4866 - Cancer-associated fibroblasts-derived VEGFA mediates the migration of gastric cancer cells through VEGFR1
Presenter: xiaoxun Wang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4934 - Risk prediction of metastasis through study of circulating tumor cells
Presenter: Panagiotis Apostolou
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3289 - First step to metastasis: miRNAome abnormalities impair cell-cell adhesion and facilitate detachment of breast cancer cells
Presenter: Volodymyr Halytskiy
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4110 - Extracellular matrix of normal brain tissue is affected by temozolomide during anti-glioblastoma treatment
Presenter: Alexandra Tsidulko
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1526 - Study of the activation of TLR receptors in neurospheres from glioblastoma cells in vitro
Presenter: David Albert Bellver
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4862 - 5-Fluorouracil induced up-regulation of exosomal PD-L1 causing immunosuppression in gastric cancer patients
Presenter: Zhang Min
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
635 - Thrombocytosis and leukocytosis: are they negative prognostic factors in solid tumours?
Presenter: Filip Kohutek
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract